BVAC-B is immunotherapeutic vaccine using B-Cell and Monocytes as antigen presenting cell. This study is Open-label, Accelerated titration, Multiple dosing study to evaluate the safety, tolerability, immune response and pre-efficacy of BVAC-B in patients with progressive or recurrent HER2/neu positive gastric cancer after failure to standard care. 9-27 patients will be enrolled.

Inclusion Criteria:

• Progressive or recurrent HER2/neu positive(IHC 1+≥) gastric cancer
• Received 1 or more chemotherapy or radiotherapy as prior therapy for progressive or recurrent tumor lesion
• At least 1 measurable lesion according to RECIST(ver 1.1)
• Ages above 19
• ECOG performance status between 0 to 2
• Patients meets the blood test standards in the screening test
• Patients meets the blood chemistry test standards in the screening test
• Patients who has agreed to a medically accepted contraceptive in this clinical trial
• Patients at least six months or more of survival can be expected
• Patients decided to participate in this clinical trial and signed written informed consent

Exclusion Criteria:

• Histopathology is a neuroendocrine or small cell carcinoma
• History of brain metastasis or signs of brain metastasis
• Clinical diagnosis of hepatitis C or hepatitis B
• Clinical diagnosis of human immunodeficiency virus (HIV)
• History of HIV infection
• Patients with heart failure, coronary artery disease(CAD) or Myocardial infarction in 6 month prior to screening. (LVEF is lower than 50% in screening visit)
• Administered the drug for other clinical trials within 4weeks before participate in this trial
• Administered any vaccines within 4weeks before participate in this trial (4 weeks for live vaccine, 2 weeks for other inactivated vaccine)
• Administered the granulocytes concentrates within 3 months before the screening visit
• Received chemotherapy or radiation therapy within 2 weeks before the 1st administration of investigational drug(BVAC-B)
• Received following formulation within 1 months before the screening visit : Chronic steroids(more than 5 days), immunosuppressant or immunomodulatory agents. G-CSF
• Patients who have participated in the clinical trial of a immunotherapeutic vaccine within 1 year or immunotherapy within 3 months before the screening visit
• Patients who is pregnant or breast-feeding
• Patients who researchers has determined that participation in the clinical trial is inappropriate
• Suspected to have other progressive cancer or malignant tumor needs treatment in 3 years. Completely treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, thyroid carcinoma, cervical intraepithelial neoplasia are not included